Experience Sell-side Advice

Peak Proteins




Sale of 100% shares





Translink advised Peak Proteins of the 100% sale to Sygnature Discovery

Translink Corporate Finance in the UK advised a rapidly growing contract research organisation, Peak Proteins, on the 100% sale to a leading independent integrated drug discovery and non-clinical services company, Sygnature Discovery.

Peak Proteins is a rapidly growing contract research organisation that provides three key services: tailor-made protein reagents, protein structure information using X-ray crystallography and protein mass spectrometry.

Peak Proteins will continue to operate out of their new research facility in Macclesfield, near Sygnature’s Alderley Edge site. The Peak Proteins leadership team will also remain with the business.
The acquisition will expand the scope of Sygnature’s in-house drug development capabilities, bringing increased value to partner projects and future patients. Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported several integrated drug discovery programmes.

The acquisition is part of Sygnature’s strategic plan to continuously invest in the expansion of its drug discovery capabilities. Steve Young, Sygnature Discovery VP of Business Development, says: “The Peak Proteins expertise will sit perfectly alongside our HTS and extensive biophysics capabilities. Their world-class expertise in protein crystallography will enhance our fragment screening and analysis activities, as well as our structure-based drug design work.”

Mark Abbott, CEO of Peak Proteins, said: “We have always valued Sygnature Discovery’s support and are now really pleased to be joining them. It will enable us to work more closely on integrated projects in addition to our existing client base where we provide both proteins and protein structural information on a very wide range of proteins to clients across the world.”

This transaction represents the fourth acquisition that Sygnature Discovery has made in the last four years, and the first since Five Arrows Principal Investments made a significant equity investment in the company in 2021.

Sygnature Discovery’s CEO, Simon Hirst, stated: “We are delighted to welcome Peak Proteins and its talented scientists to the Sygnature family. Accessing high quality proteins efficiently is often a major stumbling for projects and protein structural information is still the gold standard when it comes to drug design. The closer integration of Peak Proteins into our projects will be extremely powerful in driving programmes forward.”

Are you interested in selling your company or acquiring a company?
For information on how we carry out such projects, please visit our website or contact us directly. The Holon team are available to help with any enquiries you may have. Contact us

Company information


Peak Proteins was set up in 2014 by scientists previously from AstraZeneca’s protein biochemistry and structural biology groups. Spearheaded by CEO, Mark Abbott, the company now employs 35 people, most of whom are scientists. Its core technologies include protein expression and purification, alongside protein crystallography, structure determination and mass spectrometry services.


Investor information


Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. Private equity-backed, the company operates fully enabled research facilities in the UK, housing more than 400 research scientists (over 80% of whom hold a PhD), and has an office presence in Cambridge, MA, and South San Francisco, CA, in the US.